Is AXXA or JNJ a better dividend investment in 2026?

AXXA currently yields 500000.00% with a 5% 5-year dividend growth rate. JNJ yields 2.13% with 5.8% growth. The better choice depends on your goal: AXXA offers higher current income.

What is the dividend yield difference between AXXA and JNJ?

AXXA has a forward dividend yield of 500000.00% ($2.00/share annually). JNJ yields 2.13% ($5.20/share annually). The yield gap is 499997.87 percentage points.

Home › Compare › AXXA vs JNJ

AXXA vs JNJ: Dividend Comparison 2026

AXXA yields 500000.00% · JNJ yields 2.13%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 AXXA wins by $4.663521010693878e+33M in total portfolio value

INVESTMENT

TIME HORIZON10 years

AXXA

● Live price

500000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.663521010693878e+33M

Annual income

$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00

Full AXXA calculator →

JNJ

Johnson & Johnson

● Live price

2.13%

Share price

$244.44

Annual div

$5.20

5Y div CAGR

28%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.3K

Annual income

$4,689.40

Full JNJ calculator →

Portfolio growth — AXXA vs JNJ

📍 AXXA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	AXXA	JNJ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, AXXA + JNJ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

AXXA pays

JNJ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AXXA

Annual income on $10K today (after 15% tax)

$42,500,000.00/yr

After 10yr DRIP, annual income (after tax)

$3,962,433,917,637,946,000,000,000,000,000,000,000,000.00/yr

JNJ

Annual income on $10K today (after 15% tax)

$180.82/yr

After 10yr DRIP, annual income (after tax)

$3,985.99/yr

At 15% tax rate, AXXA beats the other by $3,962,433,917,637,946,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AXXA + JNJ for your $10,000?

AXXA: 50%JNJ: 50%

100% JNJ50/50100% AXXA

Portfolio after 10yr

$2.331760505346939e+33M

Annual income

$2,330,843,480,963,498,000,000,000,000,000,000,000,000.00/yr

Blended yield

99.96%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

AXXA

No analyst data

Altman Z

1.6

Piotroski

7/9

JNJ

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$228.73

-6.4% upside vs current

Range: $190.00 — $265.00

Altman Z

5.2

Piotroski

4/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AXXA buys

JNJ buys

No recent congressional trades found for AXXA or JNJ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricAXXAJNJ

Forward yield	500000.00% ✓	2.13%
Annual dividend / share	$2.00	$5.20 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	28% ✓
Portfolio after 10y	$4.663521010693878e+33M	$30.3K ✓
Annual income after 10y	$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00 ✓	$4,689.40
Total dividends collected	$4.6634009849658873e+33M	$15.4K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: AXXA vs JNJ ($10,000, DRIP)

Year	AXXA Portfolio	AXXA Income/yr	JNJ Portfolio	JNJ Income/yr	Gap
1← crossover	$50,010,700	$50,000,000.00	$10,592	$272.30	+$50.00M → AXXA
2	$233,748,371,262	$233,694,859,813.08	$11,289	$357.73	+$233748.36M → AXXA
3	$1,021,074,511,412,696	$1,020,824,400,655,446.10	$12,123	$472.89	+$1021074511.40M → AXXA
4	$4,168,597,328,794,951,700	$4,167,504,779,067,739,000.00	$13,141	$629.86	+$4168597328794.94M → AXXA
5	$15,905,475,114,600,665,000,000	$15,901,014,715,458,854,000,000.00	$14,408	$846.81	+$15905475114600664.00M → AXXA
6	$56,718,938,532,531,060,000,000,000	$56,701,919,674,158,435,000,000,000.00	$16,021	$1,151.60	+$56718938532531060736.00M → AXXA
7	$189,031,807,435,623,860,000,000,000,000	$188,971,118,171,394,040,000,000,000,000.00	$18,122	$1,588.22	+$1.8903180743562385e+23M → AXXA
8	$588,799,810,476,518,260,000,000,000,000,000	$588,597,546,442,562,100,000,000,000,000,000.00	$20,930	$2,228.20	+$5.8879981047651824e+26M → AXXA
9	$1,714,064,268,114,722,600,000,000,000,000,000,000	$1,713,434,252,317,512,700,000,000,000,000,000,000.00	$24,792	$3,191.91	+$1.7140642681147225e+30M → AXXA
10	$4,663,521,010,693,878,300,000,000,000,000,000,000,000	$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00	$30,274	$4,689.40	+$4.663521010693878e+33M → AXXA

AXXA vs JNJ: Complete Analysis 2026

AXXA — Stock

Exxe Group Inc. focuses on real estate, sustainable technology, media, agribusiness, and financial services businesses. The company buys, develops, and manages real estate properties, including condominiums, hotels, vacation homes, residential complexes, senior living communities, offices, and self-storage facilities. It also provides financing and execution services; advises issuers and investors through financing, acquisition, and exit strategies; and delivers services to investors through media and tech. The company was formerly known as Telecorp, Inc. Exxe Group Inc. was incorporated in 2009 and is based in New York, New York.

Full AXXA Calculator →

JNJ — Healthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →

📬

Get this AXXA vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AXXA vs SCHD AXXA vs JEPI AXXA vs O AXXA vs KO AXXA vs MAIN AXXA vs ABBV AXXA vs MRK AXXA vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.